PURPOSE: The purpose of this study was to further define the biology of the 11q- neuroblastoma tumor subgroup by the integration of array-based comparative genomic hybridization with microRNA (miRNA) expression profiling data to determine if improved patient stratification is possible. EXPERIMENTAL DESIGN: A set of primary neuroblastoma (n = 160), which was broadly representative of all genetic subtypes, was analyzed by array-based comparative genomic hybridization and for the expression of 430 miRNAs. A 15-miRNA expression signature previously shown to be predictive of clinical outcome was used to analyze an independent cohort of 11q- tumors (n = 37). RESULTS: Loss of 4p and gain of 7q occurred at a significantly higher frequency in the 11q- tumors, further defining the genetic characteristics of this subtype. The 11q- tumors could be split into two subgroups using a miRNA expression survival signature that differed significantly in clinical outcome and the overall frequency of large-scale genomic imbalances, with the poor survival subgroup having significantly more imbalances. miRNAs from the expression signature, which were upregulated in unfavorable tumors, were predicted to target downregulated genes from a published mRNA expression classifier of clinical outcome at a higher-than-expected frequency, indicating the miRNAs might contribute to the regulation of genes within the signature. CONCLUSION: We show that two distinct biological subtypes of neuroblastoma with loss of 11q occur, which differ in their miRNA expression profiles, frequency of segmental imbalances, and clinical outcome. A miRNA expression signature, combined with an analysis of segmental imbalances, provides greater prediction of event-free survival and overall survival outcomes than 11q status by itself, improving patient stratification. Copyright 2010 AACR.
PURPOSE: The purpose of this study was to further define the biology of the 11q- neuroblastoma tumorsubgroup by the integration of array-based comparative genomic hybridization with microRNA (miRNA) expression profiling data to determine if improved patient stratification is possible. EXPERIMENTAL DESIGN: A set of primary neuroblastoma (n = 160), which was broadly representative of all genetic subtypes, was analyzed by array-based comparative genomic hybridization and for the expression of 430 miRNAs. A 15-miRNA expression signature previously shown to be predictive of clinical outcome was used to analyze an independent cohort of 11q- tumors (n = 37). RESULTS: Loss of 4p and gain of 7q occurred at a significantly higher frequency in the 11q- tumors, further defining the genetic characteristics of this subtype. The 11q- tumors could be split into two subgroups using a miRNA expression survival signature that differed significantly in clinical outcome and the overall frequency of large-scale genomic imbalances, with the poor survival subgroup having significantly more imbalances. miRNAs from the expression signature, which were upregulated in unfavorable tumors, were predicted to target downregulated genes from a published mRNA expression classifier of clinical outcome at a higher-than-expected frequency, indicating the miRNAs might contribute to the regulation of genes within the signature. CONCLUSION: We show that two distinct biological subtypes of neuroblastoma with loss of 11q occur, which differ in their miRNA expression profiles, frequency of segmental imbalances, and clinical outcome. A miRNA expression signature, combined with an analysis of segmental imbalances, provides greater prediction of event-free survival and overall survival outcomes than 11q status by itself, improving patient stratification. Copyright 2010 AACR.
Authors: Evi Michels; Jo Vandesompele; Katleen De Preter; Jasmien Hoebeeck; Joëlle Vermeulen; Alexander Schramm; Jan J Molenaar; Björn Menten; Barbara Marques; Raymond L Stallings; Valérie Combaret; Christine Devalck; Anne De Paepe; Rogier Versteeg; Angelika Eggert; Geneviève Laureys; Nadine Van Roy; Frank Speleman Journal: Genes Chromosomes Cancer Date: 2007-12 Impact factor: 5.006
Authors: Marilena V Iorio; Patrizia Casalini; Claudia Piovan; Gianpiero Di Leva; Andrea Merlo; Tiziana Triulzi; Sylvie Ménard; Carlo M Croce; Elda Tagliabue Journal: Cancer Res Date: 2009-03-10 Impact factor: 12.701
Authors: Yael P Mosse; Sharon J Diskin; Nora Wasserman; Katherine Rinaldi; Edward F Attiyeh; Kristina Cole; Jayanti Jagannathan; Karishma Bhambhani; Cynthia Winter; John M Maris Journal: Genes Chromosomes Cancer Date: 2007-10 Impact factor: 5.006
Authors: G Schleiermacher; J Michon; I Huon; C Dubois d'Enghien; J Klijanienko; H Brisse; A Ribeiro; V Mosseri; H Rubie; C Munzer; C Thomas; D Valteau-Couanet; A Auvrignon; D Plantaz; O Delattre; J Couturier Journal: Br J Cancer Date: 2007-06-19 Impact factor: 7.640
Authors: Julie Bienertova-Vasku; Pavel Mazanek; Renata Hezova; Anna Curdova; Jana Nekvindova; Leos Kren; Jaroslav Sterba; Ondrej Slaby Journal: Tumour Biol Date: 2013-06-20
Authors: Isabella Bray; Amanda Tivnan; Kenneth Bryan; Niamh H Foley; Karen M Watters; Lorraine Tracey; Andrew M Davidoff; Raymond L Stallings Journal: Cancer Lett Date: 2011-04-01 Impact factor: 8.679
Authors: Amanda Tivnan; Niamh H Foley; Lorraine Tracey; Andrew M Davidoff; Raymond L Stallings Journal: Anticancer Res Date: 2010-11 Impact factor: 2.480
Authors: A P Berbegall; E Villamón; M Piqueras; I Tadeo; A Djos; P F Ambros; T Martinsson; I M Ambros; A Cañete; V Castel; S Navarro; R Noguera Journal: Oncogene Date: 2015-06-29 Impact factor: 9.867
Authors: N H Foley; I Bray; K M Watters; S Das; K Bryan; T Bernas; J H M Prehn; R L Stallings Journal: Cell Death Differ Date: 2011-01-07 Impact factor: 15.828